ADMA Biologics, Inc.
ADMAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the. With a market capitalization of $2.39B, it sits in mid-cap territory. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Market Cap
$2.39B
Beta
0.69
P/E (TTM)
15.26
P/E (Fwd)
11.32
EPS (TTM)
$0.70
EPS (Fwd)
$0.94
ROE
41.9%
ROA
21.8%
Cash
$136.0M
Total Debt
$203.8M
Free CF
$54.8M
52W Change
-31.5%
Annual Financials
Cash vs Debt
Where ADMA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ADMA finished 16.77% above its 150-day moving average ($9.48) and 1.77% below its 200-day moving average ($11.27). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ADMA overbought or oversold?
At the October 20, 2026 close, ADMA's RSI(14) was 74.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, ADMA has $136.0M in cash with $203.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $54.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 41.9% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 21.8% further supports the picture of efficient asset utilization. Revenue has grown from $154.1M (2022) to $510.2M (2025), reflecting a 231% increase over the period.
The relatively low beta of 0.69 suggests ADMA is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ADMA Biologics, Inc.'s trajectory.